Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 8:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Response Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00058734
View directory record Official record
Conditions
HIV Infections
Interventions
Dendritic Cells Pulsed with HIV antigens
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2007 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional

18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma

NCT01825902
View directory record Official record
Conditions
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
fluorine F 18 fluorothymidine, fludeoxyglucose F 18, positron emission tomography, diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Phase 2 Interventional

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

NCT00244959
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 16, 2026, 8:56 PM EDT
Completed No phase listed Observational

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

NCT01460641
View directory record Official record
Conditions
Rectal Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional

Early Markers of Disease and Response to Therapy

NCT04118153
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Abatacept
Drug
Lead sponsor
Sandra Lord, MD
Other
Eligibility
6 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)

NCT01871545
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Phase 3 Interventional

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

NCT00171041
View directory record Official record
Conditions
Hypertension
Interventions
valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 16 Years
Enrollment
265 participants
Timeline
2002 – 2006
U.S. locations
1
States / cities
E.Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 16, 2026, 8:56 PM EDT
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis

NCT00678470
View directory record Official record
Conditions
Moderate to Severe Psoriasis
Interventions
Intralesional Alefacept
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 16, 2026, 8:56 PM EDT
Active, not recruiting Phase 2 Interventional

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT05143840
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions
Single Agent Asciminib, Low TKI, Elective Free Treatment
Drug · Combination Product · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Phase 1 Interventional

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00001113
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 16, 2026, 8:56 PM EDT
Completed No phase listed Observational

FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents

NCT02055586
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorine F 18 fluorothymidine, positron emission tomography, magnetic resonance imaging
Other · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 16, 2026, 8:56 PM EDT
Withdrawn Not applicable Interventional

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE

NCT04855370
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Embolus/Emboli, Pulmonary Disease, Pulmonary Embolism and Thrombosis, Pulmonary Embolism Subacute Massive, Pulmonary Embolism Acute Massive
Interventions
Non-invasive hemodynamic measurements
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 16, 2026, 8:56 PM EDT
Terminated Not applicable Interventional

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma

NCT00953446
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 16, 2026, 8:56 PM EDT
Completed No phase listed Observational

Advanced MR Imaging in Sarcoma Patients

NCT02705391
View directory record Official record
Conditions
Sarcoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

NCT01292473
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Placebo, Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
La Jolla, California • Los Angeles, California • Redwood City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Not applicable Interventional

Optimizing Overactive Bladder Treatment

NCT03904407
View directory record Official record
Conditions
Overactive Bladder
Interventions
Lactobacillus Probiotic Capsule, Matching Lactobacillus Probiotic Placebo Capsule
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Hillsborough, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Not applicable Interventional Results available

Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder

NCT04076644
View directory record Official record
Conditions
MDD
Interventions
TMS treatment
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Results available

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

NCT03570918
View directory record Official record
Conditions
HIV-1-infection
Interventions
MGD014
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 16, 2026, 8:56 PM EDT
Recruiting Not applicable Interventional

Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response

NCT04588025
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Point-of-care Portable Perfusion Phantom, P4
Device
Lead sponsor
Ohio State University
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 16, 2026, 8:56 PM EDT
Not listed Phase 1 Interventional

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

NCT00002449
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
23
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 16, 2026, 8:56 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

NCT00004249
View directory record Official record
Conditions
Lung Cancer
Interventions
QS21, keyhole limpet hemocyanin, polysialic acid
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 16, 2026, 8:56 PM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 16, 2026, 8:56 PM EDT